Top Markets
#1 GoPlus Security GoPlus Security +31.51%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.70%
#3 Status Status +17.55%
#4 Wrapped NXM Wrapped NXM +14.47%
#5 BankrCoin BankrCoin +11.13%
#6 Pons Pons +10.73%
#7 Bedrock Bedrock +10.01%
#8 Ontology Gas Ontology Gas +9.25%
#9 DMT-NAT DMT-NAT +8.78%
#10 o1.exchange o1.exchange +7.41%
Coin of the day
GoPlus Security GoPlus Security
Settings
Language
ENGLISH
Currency
USD
Theme
Pure Biologics Spólka Akcyjna Pure Biologics Spólka Akcyjna

Pure Biologics Spólka Akcyjna

PUR
Rank in Stocks #33923
Pure Biologics Spólka Akcyjna operates as a biopharmaceutical enterprise,... Pure Biologics Spólka Akcyjna operates as a biopharmaceutical enterprise, concentrating its efforts on the discovery and development of novel biological pharmaceuticals and targeted, non-systemic treatments. The company's key therapeutic interests span immuno-oncology, various autoimmune conditions, and rare diseases. Its capabilities encompass the entire process for antibodies and aptamers, from their initial creation and purification to detailed analysis and characterization. Additionally, Pure Biologics is skilled in the design, development, and rigorous validation of diagnostic and research assays, while also advancing technology platforms for the precise selection of active therapeutic molecules. A significant offering is PureApta, a adaptable platform engineered for the in vitro selection of modified aptamers, suitable for both medical treatment and diagnostic applications. The firm is also actively pursuing the development of localized therapies aimed at assisting individuals afflicted by neurological autoimmune disorders, including conditions like neuromyelitis optica and myasthenia gravis. Founded in 2010, Pure Biologics Spólka Akcyjna is headquartered in Wroclaw, Poland.
Share Price
$0.8248572
Last synced: 2026-08-07
Market Cap
$6.60M
Change (1 day)
35.02%
Change (1 year)
-54.35%
Country
PL
Trade Pure Biologics Spólka Akcyjna (PUR)

Category

Healthcare
P/E ratio for Pure Biologics Spólka Akcyjna (PUR)
P/E ratio as of 2026 TTM: 0
According to Pure Biologics Spólka Akcyjna latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Pure Biologics Spólka Akcyjna from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.